GSK launched a 3-year cost-savings program to simplify the organization, freeing resources to accelerate R&D investment.
Savings will be mainly reinvested in late-stage pipeline priorities, with some used to support margins through the 2028-2030 dolutegravir patent expiry.
Plans include accelerating 7 key late-stage assets across 18 indications, targeting 20+ phase III trial starts in 2026.
GSK will establish a new flagship R&D center on the UK’s Cambridge Biomedical Campus to deepen integration with the local life-sciences ecosystem.
GSK•
